StockWatch
·

SMS Lifesciences India Ltd Q2 FY27 Results

HALEOSLABSQ2 FY27 Results
Filing
Result:Weak· Market: Flat#Margin squeeze#Base effect
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue91.3825.3%12.3%
Total Income91.4624.6%11.8%
Expenditure89.4527.9%22.0%
PBT2.0141.6%76.3%
Net Profit1.764.4%72.6%
OPM9.11%3.39pp7.57pp
NPM1.92%0.59pp5.94pp
EPS10.7723.1%46.7%
View full financials

Pharma/manufacturing lens on adjusted PAT: revenue grew 12.3% but cost-of-materials spike crushed OPM to 9.1% from 16.7% and PAT fell 72.6% YoY, a clear core-margin deterioration despite top-line growth.

Q2 FY-2027 RESULTS · HALEOSLABS

Haleos Labs Q2 FY27: consolidated PAT falls 73% YoY on margin squeeze, revenue up 12%

PAT -72.6% YoY · revenue +12.3% · margins compressing

11 Nov 2026 · 3 min read
Revenue

₹91.38 Cr

+12.3% YoY

PAT (consolidated)

₹1.76 Cr

-72.6% YoY

Net margin

1.92%

-5.9pp YoY

EPS

₹10.77

Haleos Labs (formerly SMS Lifesciences) reported consolidated revenue from operations of ₹91.38 Cr for Q2 FY27 (quarter ended September 30, 2026), up 12.3% YoY from ₹81.37 Cr and up 25.3% QoQ from ₹72.94 Cr in Q1 FY27. But consolidated PAT fell to ₹1.76 Cr, down 72.6% YoY from ₹6.43 Cr and down 4.4% QoQ from ₹1.84 Cr — profit did not follow the topline, so the YoY read is margin compression, not the sequential pickup the QoQ revenue number alone might suggest.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹91.38 Cr+25.3%+12.3%
Expenses₹89.45 Cr+27.8%+22%
PAT₹1.76 Cr-4.4%-72.6%
Net margin1.92%-0.6pp-5.9pp
EPS₹10.77+23.1%-46.7%

The squeeze sits on the cost-of-materials line: cost of materials consumed rose to 54.2% of revenue (₹49.50 Cr) from 47.9% a year ago (₹39.02 Cr), pulling operating margin down to 9.1% from 16.68% YoY and 12.50% in Q1 FY27; net margin fell to 1.9% from 7.86% YoY. Finance costs also rose 32.9% YoY to ₹2.15 Cr as borrowings increased (consolidated current borrowings ₹73.35 Cr vs ₹58.89 Cr at FY26-end) to fund a capex ramp — capital work-in-progress nearly tripled to ₹30.03 Cr from ₹10.42 Cr at March 2026 — lifting depreciation 9.3% YoY to ₹4.25 Cr.

₹
1,372.41,438.531,504.651,570.771,636.91,409.408-1009-0209-2510-2111-11Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹1,409.4, down 10.8% over the past month of trading.

₹ Cr
02.484.967.454.38Q1 FY26rev ₹83 Cr6.43Q2 FY26rev ₹81 Cr6.65Q3 FY26rev ₹95 Cr0.34Q4 FY26rev ₹75 Cr1.84Q1 FY27rev ₹73 Cr1.76Q2 FY27rev ₹91 Cr
Quarterly consolidated PAT, ₹ Crore

Standalone PAT of ₹4.31 Cr was materially stronger than the consolidated ₹1.76 Cr because subsidiary Mahi Drugs Pvt Ltd swung to a ₹3.74 Cr net loss on ₹8.30 Cr revenue this quarter. Management issued no press release and no prior guidance is on record for this result, and with effectively no analyst coverage submitting estimates, there is no street consensus to benchmark against — this print stands on its own numbers. Concurrently, the board gave in-principle approval for a Strategic Alliance and Collaboration Agreement with HRV Global Life Sciences for joint API R&D, contract manufacturing and commercialisation (terms pending definitive-agreement execution) — a continuation of the orphan/niche-API tie-up the two first announced in January 2026, though it carries no numbers yet to assess. The quarter's other disclosed event, a subsidiary clearing a USFDA inspection with zero observations (September 18, 2026), speaks to manufacturing-quality standing even as that same subsidiary cohort weighed on group profitability.

  • W1

    Raw-material cost ratio (54.2% of revenue this quarter vs ~48% a year ago) — watch for normalization as the key margin-recovery signal.

  • W2

    Mahi Drugs' loss trajectory (₹3.74 Cr loss this quarter) — whether the subsidiary narrows losses or keeps dragging consolidated PAT.

  • W3

    Execution and disclosed terms of the definitive agreement with HRV Global Life Sciences, following the board's in-principle approval.

Consolidated PAT (₹1.76 Cr, total for period) is well below standalone PAT (₹4.31 Cr) because subsidiary Mahi Drugs Pvt Ltd posted a ₹3.74 Cr net loss this quarter on ₹8.30 Cr revenue (per auditor's review note); profit attributable to parent shareholders was ₹3.26 Cr vs a ₹1.50 Cr loss attributed to non-controlling interest. No exceptional items in either statement; EPS is computed on profit attributable to owners, not the total PAT line.

Informational and educational content only. Not investment advice.